{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T02:27:29Z","timestamp":1740104849048,"version":"3.37.3"},"reference-count":24,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Surgical Oncology"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The absolute requirement for a long\u2010term favorable result with cytoreductive surgery for pseudomyxoma peritonei is a complete resection of all visible disease. A combination of parietal peritonectomy procedures and visceral resections is required for this to occur. The cytoreductive surgery is supplemented by hyperthermic intraperitoneal chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched our database and secured files for patients who required a total gastrectomy and a total colectomy to achieve a complete cytoreductive surgery. Survival of low\u2010grade mucinous neoplasm (LAMN) and mucinous appendiceal adenocarcinoma (MACA) histologies were determined. Clinical and histologic variables were assessed for their impact on survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirteen of 450 patients (2.9%) with LAMN histology and 14 of 186 patients (7.5%) with MACA histology had these visceral resections. Median survival of these 27 patients was 10 years. LAMN and MACA patients showed the same survival. For LAMN histology, this requirement for extensive visceral resection markedly reduced survival (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). For MACA, there was no adverse impact on survival (<jats:italic>p<\/jats:italic>\u2009=\u20090.4359). Class 4 adverse events caused reduced survival (<jats:italic>p<\/jats:italic>\u2009=\u20090.0014).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A 10\u2010year median survival accompanies total gastrectomy plus total colectomy for advanced pseudomyxoma peritonei. Systemic chemotherapy and class 4 adverse events reduced survival.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jso.27742","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T20:05:46Z","timestamp":1719518746000},"page":"1263-1273","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Critical appraisal of total gastrectomy plus total colectomy with hyperthermic intraperitoneal chemotherapy as a treatment for advanced pseudomyxoma peritonei"],"prefix":"10.1002","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2431-7366","authenticated-orcid":false,"given":"Paul H.","family":"Sugarbaker","sequence":"first","affiliation":[{"name":"Program in Peritoneal Surface Malignancy Washington Cancer Institute Washington District of Columbia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Chang","sequence":"additional","affiliation":[{"name":"Westat Rockville Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.26506"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.27211"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199501000-00004"},{"key":"e_1_2_8_5_1","first-page":"49","article-title":"Gastrointestinal decompression after total gastrectomy using a side duodenostomy","volume":"9","author":"Zanarini D","year":"1996","journal-title":"Reg Cancer Treat"},{"key":"e_1_2_8_6_1","first-page":"47","volume-title":"Cancer chemotherapy for peritoneal metastases. Pharmacology and treatment","author":"Van der Speeten K","year":"2017"},{"issue":"1","key":"e_1_2_8_7_1","first-page":"49","article-title":"Current methodologies for clinical assessment of patients with peritoneal carcinomatosis","volume":"15","author":"Jacquet P","year":"1996","journal-title":"J Exp Clin Cancer Res"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2168.2000.01553.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199512000-00006"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200308000-00006"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-12864-8"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-006-9187-5"},{"key":"e_1_2_8_13_1","first-page":"207","volume-title":"Patient\u2010 and treatment\u2010related variables, adverse events and their statistical relationship for treatment of peritoneal metastases","author":"Sugarbaker PH","year":"2017"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199502000-00002"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1023791229361"},{"key":"e_1_2_8_16_1","first-page":"233","article-title":"Pseudomyxoma peritonei syndrome","volume":"30","author":"Sugarbaker PH","year":"1996","journal-title":"Adv Surg"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2016.04.059"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/ejso.2001.1238"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.27220"},{"key":"e_1_2_8_20_1","first-page":"17","volume-title":"An overview of peritonectomy, visceral resection, and therapeutic laparoscopy for peritoneal surface malignancy","author":"Sugarbaker PH","year":"2017"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-017-5853-z"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.27087"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/pubmed\/fdl048"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.9674"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1515\/pp-2017-0012"}],"container-title":["Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.27742","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T05:34:07Z","timestamp":1739511247000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jso.27742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1002\/jso.27742"],"URL":"https:\/\/doi.org\/10.1002\/jso.27742","archive":["Portico"],"relation":{},"ISSN":["0022-4790","1096-9098"],"issn-type":[{"type":"print","value":"0022-4790"},{"type":"electronic","value":"1096-9098"}],"subject":[],"published":{"date-parts":[[2024,6,27]]},"assertion":[{"value":"2024-05-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}